Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.070
-0.090 (-4.17%)
At close: Jun 1, 2026, 4:00 PM EDT
2.080
+0.010 (0.48%)
After-hours: Jun 1, 2026, 4:36 PM EDT
Alector Employees
Alector had 103 employees as of December 31, 2025. The number of employees decreased by 135 or -56.72% compared to the previous year.
Employees
103
Change
-135
Growth
-56.72%
Revenue / Employee
$178,806
Profits / Employee
-$1,217,359
Market Cap
229.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | -135 | -56.72% |
| Sep 30, 2025 | 156 | -85 | -35.27% |
| Jun 30, 2025 | 163 | -82 | -33.47% |
| Mar 31, 2025 | 175 | -69 | -28.28% |
| Dec 31, 2024 | 238 | -6 | -2.46% |
| Sep 30, 2024 | 241 | -5 | -2.03% |
| Jun 30, 2024 | 245 | 6 | 2.51% |
| Mar 31, 2024 | 244 | -29 | -10.62% |
| Dec 31, 2023 | 244 | -29 | -10.62% |
| Sep 30, 2023 | 246 | -23 | -8.55% |
| Jun 30, 2023 | 239 | -30 | -11.15% |
| Mar 31, 2023 | 273 | 36 | 15.19% |
| Dec 31, 2022 | 273 | 65 | 31.25% |
| Sep 30, 2022 | 269 | 84 | 45.41% |
| Jun 30, 2022 | 269 | 85 | 46.20% |
| Mar 31, 2022 | 237 | 56 | 30.94% |
| Dec 31, 2021 | 208 | 37 | 21.64% |
| Sep 30, 2021 | 185 | 23 | 14.20% |
| Jun 30, 2021 | 184 | 31 | 20.26% |
| Mar 31, 2021 | 181 | 55 | 43.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Coherus Oncology | 145 |
| Voyager Therapeutics | 141 |
| Nkarta | 108 |
| Foghorn Therapeutics | 106 |
| Caribou Biosciences | 97 |
| Orchestra BioMed Holdings | 86 |
| Compugen | 75 |
ALEC News
- 24 days ago - Alector reports Q1 EPS (21c), consensus (28c) - TheFly
- 25 days ago - Alector Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 25 days ago - Alector Quarterly report: Q1 2026 - Filings
- 25 days ago - Alector Earnings release: Q1 2026 - Filings
- 4 weeks ago - Alector price target raised to $2 from 90c at Morgan Stanley - TheFly
- 4 weeks ago - Alector to discontinue PROGRESS-AD trial of nivisnebart - TheFly
- 4 weeks ago - Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis - GlobeNewsWire
- 4 weeks ago - Alector Proxy statement: Proxy filing - Filings